B-lymphoblastic lymphoma (B-LBL) is a rare, aggressive non-Hodgkin lymphoma. Primary cutaneous involvement is extremely uncommon, contributing to diagnostic delays, treatment challenges and poor prognosis. We report a 53-year-old woman with relapsed/refractory primary cutaneous B-LBL who, after multiple treatments, achieved rapid and durable systemic regression via chimeric antigen receptor T-cell (CAR-T) therapy.
Gan et al. (Tue,) studied this question.